Monterey Bio Acquisition Corporation (MTRY) Research

Monterey Bio Acquisition Corporation currently lacks substantial operational activities. Its primary goal is to achieve a business combination—including but not limited to mergers, capital stock exchanges, asset acquisitions, or reorganizations—with companies in the biotechnology industry. The firm, established in 2020, was formerly known as Chardan FinTech Acquisition Corp. and rebranded to Monterey Bio Acquisition Corporation in April 2021. It is headquartered in New York, New York.

Market snapshot

Symbol
MTRY
Price
$11.14
Day change
-0.27%
Market cap
$48.3M
P/E ratio
-25.14x
52-week range
10.21-12.0
Sector
Financial Services
Industry
Shell Companies

Peer companies

  • Atlantic Coastal Acquisition Corp. II (ACAB)
  • GRIID Infrastructure Inc. Common Stock (GRDI)
  • Graphjet Technology (GTI)
  • MicroCloud Hologram Inc. (HOLO)
  • Prospector Capital Corp. (PRSR)
  • Roth Ch Acquisition V Co. (ROCL)
  • Vision Sensing Acquisition Corp. (VSAC)
  • Zeo Energy Corp. (ZEO)

Recent insider activity

  • Chardan Monterey Investments LLC — P-Purchase (478125 shares) on 2023-03-09
  • Chardan Monterey Investments LLC — S-Sale (13125 shares) on 2023-03-09
  • Chardan Monterey Investments LLC — trade (0 shares) on 2022-09-29
  • GROSSMAN JONAS — P-Purchase (478125 shares) on 2023-03-09
  • GROSSMAN JONAS — S-Sale (13125 shares) on 2023-03-09

Open Monterey Bio Acquisition Corporation (MTRY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.